At-Home Blood Collection Devices Market

The at-home blood collection devices market is projected to reach USD 135 million by 2029 from an estimated USD 93 million in 2024, at a CAGR of 7.6% during the forecast period. Increasing infectious disease bioburden and progressing lifestyle disorders in most parts of the world have increased the demand for accurate and faster home-based blood collection tools, thus feeding the growth of the at-home blood collection devices market.

The key players in this market are Trajan Group Holdings Limited (Australia), Tasso, Inc. (US), YourBio Health, Inc. (US), A. Menarini Diagnostics (UK), R-Biopharm AG (Germany), Sussex Pathology Limited (UK), ImmunoServ (UK), Labonovum (Netherlands), Alpha Laboratories (UK), Lipomic Healthcare (India), Tri-Tech Forensics (US), RDA Spot Inc (Lithuania), Spot On Sciences (US), Capitainer (Sweden), PanoHealth (US), Lameditech (South Korea), Sara Healthcare (India), Owen Mumford Ltd (UK), RedDrop Dx, Inc. (US), AdvaCare Pharma (US), Naulakha Industries (India), and Phoenix Healthcare Solutions, LLC (US).

To know about the assumptions considered for the study download the pdf brochure

As of 2023, Tasso, Inc. led in the at-home blood collection devices market. Since its very inception, products developed by Tasso have been in use in pharmaceutical clinical trials and are used across many hospitals within the US.

It does organic growth strategies, such as securing of regulatory approvals, and also the inorganic growth strategies to maintain leadership. All these strategic developments contributed to the business success and dominance in the at-home blood collection devices market.

Trajan Group Holdings Limited held a considerable market share in the at-home blood collection devices market in 2023. Geographically, the company has seven manufacturing facilities across the US, Australia, Europe, and Malaysia, along with operations in Australia, the US, Asia, and Europe. In January 2024, CliniSciences  signed an agreement with Trajan for the distribution of its Neoteryx microsampling solutions. Such strategies are expected to increase the market presence of the company, thereby contributing to its strong market growth.

YourBio Health, Inc. is among the key players in the at-home blood collection devices market. YourBio Health extends access to patients, particularly those who have limited access to healthcare centers, through at-home health monitoring and diagnostics. YourBio Health works on creating user-friendly solutions that increase the comfort and compliance of patients. The company is paying more attention to organic strategies in order to maintain a strong foothold in the market. For example, in October 2023, the company received additional regulatory clearance for its TAP Micro Select blood collection device with certification for CE Marking. Further, in April 2023, the company got 510(k) Medical Device clearance from US Food and Drug Administration (FDA) for TAP Micro Select. By being at the forefront of regulatory compliance, YourBio Health will definitely be able to increase its presence in the market with leading-edge health solutions of quality that will meet industry requirements.

Related Reports:

At-Home Blood Collection Devices Market by Product (Lancets, DBS Kits), Sample Type (Liquid, Dried), Collection Method (Push-button, Laser), Device Type (Self, Professional), Application (Diagnostics, Screening, Clinical Trials) - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]